OMER announced that the EMA CHMP issued a negative opinion on narsoplimab for TA-TMA after re-examining the prior ruling (June 2026). The European setback weighs on regulatory prospects, potentially delaying commercialization and affecting near-term milestones and valuation tied to narsoplimab's potential. Investors will watch for management updates on salvage paths, data readouts, or alternative strategies.
Cantor Fitzgerald upgrades OMER to Overweight with a $22 target after Yartemlea's stronger-than-expected launch. Payer support via NTAP and a J-code, plus Q2 revenue of $28.5M (up 11% sequentially), bolster long-term adoption and peak sales potential. The stock rose about 12%, signaling potential further upside.
EMA CHMP cited trial design flaws and limited pediatric data for Yartemlea TA-TMA, limiting interpretability. Despite FDA approval and a US launch, EMA concerns could slow European uptake. CMS J-code set for July 1, 2026 and NTAP prospects support US reimbursement, but the EMA setback keeps OMER under pressure.
Omeros Corporation's stock rose over 150%. They secured a $2.1 billion deal with Novo Nordisk. The deal is for the MASP-3 inhibitor, zaltenibart. Investor confidence improved, alleviating bankruptcy fears. Continued operations now supported for Omeros Corporation.
